Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:APS NYSE:COV CVE:LTY NASDAQ:SVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$1.71-0.6%C$1.87C$1.02▼C$21.00C$73.63M1.365,419 shs531 shsCOV(COV)$0.00$65.97▼$108.57N/AN/A3.88 million shsN/ALTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.66M0.61N/AN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences+0.58%+2.38%-31.20%-32.28%-91.92%COV(COV)0.00%0.00%0.00%0.00%0.00%LTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPSAptose BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACOV(COV)N/AN/AN/AN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ASVASinovac BiotechN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPSAptose Biosciences 4.00Strong BuyN/AN/ACOV(COV) 0.00N/AN/AN/ALTYLiberty Biopharma 0.00N/AN/AN/ASVASinovac Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPSAptose BiosciencesN/AN/AC$1.07 per share1.60C($0.92) per shareN/ACOV(COV)N/AN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AC$0.00 per share2,000.00C$0.79 per shareN/ASVASinovac Biotech$448.27M1.44$0.17 per share38.95$120.83 per share0.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPSAptose Biosciences-C$154.69M-C$5.02N/A∞N/AN/A1,017.48%-136.29%N/ACOV(COV)N/AN/A0.00N/AN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/A-C$0.16N/A∞N/AN/AN/AN/AN/ASVASinovac Biotech-$99.92MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPSAptose BiosciencesN/A0.39%N/AN/AN/ACOV(COV)N/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/ASVASinovac BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPSAptose Biosciences-117.371.055.41COV(COV)N/AN/AN/ALTYLiberty Biopharma8.190.120.12SVASinovac BiotechN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPSAptose Biosciences15.10%COV(COV)N/ALTYLiberty BiopharmaN/ASVASinovac BiotechN/AInsider OwnershipCompanyInsider OwnershipAPSAptose Biosciences17.11%COV(COV)N/ALTYLiberty BiopharmaN/ASVASinovac Biotech12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPSAptose Biosciences3143.06 millionN/ANot OptionableCOV(COV)N/AN/AN/ANot OptionableLTYLiberty BiopharmaN/A10.77 millionN/ANot OptionableSVASinovac Biotech3,26199.64 million86.89 millionOptionableLTY, APS, COV, and SVA HeadlinesRecent News About These CompaniesSINOVAC Board Sets the Record Straight on July 8 Special Meeting of ...July 13, 2025 | morningstar.comMSINOVAC Board of Directors Provides Update on Status of US$55.00 ...July 11, 2025 | morningstar.comMSINOVAC Board Sets the Record Straight on July 8 Special Meeting of ShareholdersJuly 11, 2025 | businesswire.comSinovac Biotech’s New Board Charts Future Path with Strategic InitiativesJuly 11, 2025 | tipranks.comNewly Elected Directors of Sinovac Hold the First Board MeetingJuly 10, 2025 | financialpost.comFNewly Elected Directors of Sinovac Hold the First Board MeetingJuly 10, 2025 | businesswire.comFinal Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card "AGAINST" Misguided Proposals 1 and 2 - NasdaqJuly 9, 2025 | nasdaq.comSINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former BoardJuly 9, 2025 | businesswire.comSINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend PaymentJuly 9, 2025 | businesswire.comSINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE SharesJuly 9, 2025 | businesswire.comAppeal Decision By Eastern Caribbean Supreme Court Supports Right of Prime Success and Vivo Capital to Participate in Critical Sinovac Biotech Shareholder VoteJuly 9, 2025 | businesswire.comSinovac Biotech Retains Support from Proxy Advisors Ahead of Crucial VoteJuly 8, 2025 | tipranks.comFinal Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card "AGAINST" Misguided Proposals 1 and 2July 7, 2025 | finance.yahoo.comFinal Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card “AGAINST” Misguided Proposals 1 and 2July 7, 2025 | businesswire.comFederal Court in Massachusetts Denies Vivo Capital’s Petition for Relief on SINOVACJuly 7, 2025 | finance.yahoo.comFederal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVACJuly 7, 2025 | businesswire.comLeading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in PlaceJuly 3, 2025 | businesswire.comUnited States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding SinovacJuly 2, 2025 | businesswire.comSAIF Partners: Now is Your Last Chance to Vote for Board Change at SinovacJuly 2, 2025 | businesswire.comSinovac Controlling Investors Ordered to Amend DisclosuresJuly 2, 2025 | news.bloomberglaw.comNNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 2025D-Wave, SuperQ, and Verge: A New Path Forward for Quantum?By Nathan Reiff | July 28, 2025Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]By MarketBeat Staff | July 29, 20253 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and WhyBy Leo Miller | July 16, 2025LTY, APS, COV, and SVA Company DescriptionsAptose Biosciences TSE:APSC$1.71 -0.01 (-0.58%) As of 11:04 AM EasternAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.(COV) NYSE:COVCovidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.Liberty Biopharma CVE:LTYC$2.00 +2.00 (+∞) As of 10/10/2018Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.Sinovac Biotech NASDAQ:SVASinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's White House Reset: From Political Storm to a Clearer Sky AST SpaceMobile on Track for Explosive Upside Oklo’s Stock Is Set up for a Correction—Buy It When It Bounces If Qualcomm Holds $145, Its Next Move Could Be Massive Alphabet Reclaims $200 Threshold—Bull Run Reignited? NFL and WWE Land on ESPN—The Impact on Disney and TKO Stocks Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside Apple & Trump: $100B Investment, Tariffs News Push Shares Up 13% Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access